Posts by Sandra Ansanay-Alex
Three Leading Digital Health Hubs Unite to Boost European Innovation
Three major European digital health ecosystems are teaming up to create a pan-European alliance aimed at accelerating the growth and cross-border scaling of digital health solutions. The Future of Health Grant (Switzerland), Future4care (France/Germany), and the Barcelona & Madrid Health Hub (Spain) signed partnership agreements during the Health Revolution Congress 2025 in Barcelona. Their…
Read MoreiOnctura Expands Roginolisib Trials to the US
iOnctura, a Geneva-based clinical-stage precision oncology company focused on neglected and hard-to-treat cancers, announces the expansion of its clinical trial programme for lead candidate roginolisib into the United States. Several US trial sites are now enrolling patients in the OCULE-01 Phase II study in metastatic uveal melanoma, with an additional study, led by Dr…
Read MoreBearmind and Bauer Announce Strategic Partnership
The Vaud-based medtech startup and the Canadian manufacturer of ice hockey equipment want redefine the future of ice hockey helmets through datadriven innovation This partnership combines Bauer’s industry-leading expertise in protective equipment with Bearmind’s advanced sensor and analytics platform to create the next generation of smart hockey helmets – gear that not only protects…
Read MoreAevis Victoria’s Profits Have Almost Tripled in a Decade
The Fribourg-based group of private clinics and luxury hotels (Genolier, Generale-Beaulieu Clinic Geneva, etc.) recorded profits of CHF 12.2 million after six months in 2016, up from CHF 4.5 million. Aevis Victoria posted a positive result in the first half of the year, with profits up almost threefold.Net sales also rose by 15.3% year-on-year…
Read MoreEarlySight Secures CHF 6.1 Million to Advance Vision-Saving Technology
EarlySight, a Geneva-based startup, is excited to announce the successful extension of its Seed round to CHF 6.1 million, with Zürcher Kantonalbank joining its strong syndicate of investors, which includes Verve Ventures, Nina Capital, NovaCapital, and CADFEM International GmbH. This new funding marks a significant milestone in its mission to transform retinal diagnostics. It…
Read MoreAlcon gets the International Influence Award at the Geneva Business Awards Ceremony
The winners of the 2025 Geneva Business Awards are: Taurus for the Innovation Award, Swissoja for the Industry Award, Alcon for the International Influence Award, Fondation Partage for the Special Jury Award, and Komgo SA for the Economy Award. Global eye care specialist Alcon inaugurated its global headquarters close to the Geneva airport in…
Read MoreHealthCare Konnect and Bonescreen Announce Strategic Partnership
Healthcare Konnect (HCK) and bonescreen partner to enhance early and accurate diagnosis of bone health disorders. Osteoporosis and related bone conditions affect millions worldwide, significantly impacting patient quality of life. Early detection is essential, yet conventional diagnostic methods often involve invasive procedures or expose patients to additional radiation, potentially limiting timely intervention and optimal…
Read MoreProf. Bloch and Prof. Courtine New Breakthrough for SCI Patients
In a rare double publication in Nature and Nature Medicine, landmark studies led by Professor Grégoire Courtine (EPFL), Professor Jocelyne Bloch (CHUV and University of Lausanne), and Dr. Aaron Phillips (University of Calgary) describe the development of a targeted therapy to stabilize blood pressure in SCI patients. Working with EPFL spin-off ONWARD Medical, the team…
Read MoreMecaplast Acquired by Irish Company Schivo
Mecaplast SA, is a highly specialised Swiss manufacturer of high-precision injection-moulded plastics, metals and ceramics for the medical device and life sciences sectors based in Botterens, in Canton of Fribourg. Founded in 1971, Mecaplast has earned a strong reputation for technical excellence and quality in producing mission-critical components, precision molds, and cleanroom assemblies for…
Read MoreLemna Bio Received CHF 150,000 from Venture Kick to Redefine Drug Discovery
EPFL spin-off Lemna Bio has raised CHF 150,000 from Venture Kick to develop its physics-driven AI platform, which makes biomolecular interactions more predictable, explainable, and reliable. The technology helps pharmaceutical companies identify better disease targets and design more effective therapies. Drug discovery today faces decade-long timelines, soaring costs, and a 90% clinical failure rate…
Read More